戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  can ameliorate both the direct and indirect fibroproliferative actions of TGF-beta.
2 inase 2 (HK2) is important for mediating the fibroproliferative activity of TGF-beta both in vitro an
3 ich critically ill surgical patients develop fibroproliferative acute respiratory distress syndrome.
4                 Asbestos is a carcinogen and fibroproliferative agent in lung that may cause cell sig
5                      Fibrosis, microvascular fibroproliferative alterations, and autoantibody product
6 mbating chronic rejection by inhibiting both fibroproliferative and alloimmune responses.
7       Furthermore, the findings suggest that fibroproliferative and inflammatory lesions are independ
8 ung inflammation and the development of late fibroproliferative ARDS, or if it is predictive of a ben
9 ne 125 mg i.v. every 6 hrs was initiated for fibroproliferative ARDS.
10 ecular mechanisms governing inflammatory and fibroproliferative aspects of the disorder are not clear
11 played histological characteristics of bone, fibroproliferative cells, blood vessels, and adipose tis
12 poxic pulmonary hypertension includes marked fibroproliferative changes in the pulmonary artery (PA)
13 d 11 days after symptom onset, had pulmonary fibroproliferative changes.
14 lmonary lymphatics is a critical mediator of fibroproliferative changes.
15  0.001), but they also developed obstructive fibroproliferative coronary artery lesions much earlier
16                Keloid disease is a recurrent fibroproliferative cutaneous tumor of unknown pathogenes
17 of connective tissue growth factor (CTGF), a fibroproliferative cytokine, by transforming growth fact
18                               KD is a common fibroproliferative dermal lesion with an ill-defined tre
19          Keloids are reactive or spontaneous fibroproliferative dermal tumors characterized by the ex
20 tren's disease (DD) is a common, progressive fibroproliferative disease affecting the palmar fascia o
21                          Arthrofibrosis is a fibroproliferative disease characterised by excessive de
22                  Frozen shoulder is a common fibroproliferative disease characterized by the insidiou
23                                         This fibroproliferative disease may be promoted by overproduc
24 hat controls type I collagen translation and fibroproliferative disease progression.
25  fibrosis (IPF) is an insidious inflammatory fibroproliferative disease whose cause and course before
26 ls are known to be the key effector cells of fibroproliferative disease, but the specific matrix sign
27 ession at sites of lung injury in developing fibroproliferative disease.
28 pathic pulmonary fibrosis (IPF) is a lethal, fibroproliferative disease.
29                                     Systemic fibroproliferative diseases (renal sclerosis and idiopat
30                                      Chronic fibroproliferative diseases account for approximately 45
31 ic diseases are to discuss some of the major fibroproliferative diseases and to identify the common a
32                                              Fibroproliferative diseases are driven by dysregulated t
33                               Unfortunately, fibroproliferative diseases remain intractable to curren
34  are strongly implicated in the formation of fibroproliferative diseases such as proliferative vitreo
35                                              Fibroproliferative diseases, including the pulmonary fib
36 efully help us better understand and address fibroproliferative diseases, such as idiopathic pulmonar
37 tants and are involved in other inflammation/fibroproliferative diseases, we hypothesized that the ex
38 a critical event in the genesis of pulmonary fibroproliferative diseases.
39 opment, where dysregulation is a hallmark of fibroproliferative diseases.
40 ted response has been implicated in multiple fibroproliferative diseases.
41 L-1 and has been associated with a number of fibroproliferative diseases.
42 s to the development and progression of this fibroproliferative disorder and identified TNF as a ther
43 ibrosis (IPF) is a progressive and incurable fibroproliferative disorder characterized by unrelenting
44   It is an increasingly common and disabling fibroproliferative disorder of the palmar fascia, which
45 ic pulmonary fibrosis (IPF) is a progressive fibroproliferative disorder refractory to current pharma
46              As TGFbeta is causal to various fibroproliferative disorders featuring localized or syst
47 harmacological target for immunosuppression, fibroproliferative disorders, atherosclerosis, and strok
48 e receptor CXCR3 is functionally involved in fibroproliferative disorders, including liver fibrosis.
49 ive in reducing fibrosis across a variety of fibroproliferative disorders, including preclinical mode
50  plays a central role in the pathogenesis of fibroproliferative disorders.
51 demand, given the rise of diseases linked to fibroproliferative disorders.
52 icellular protein that plays a major role in fibroproliferative disorders.
53 pathogenesis of pulmonary fibrosis and other fibroproliferative disorders.
54 ion of extracellular matrix observed in many fibroproliferative disorders.
55 ons is an effective therapeutic strategy for fibroproliferative disorders.
56 itors as potential therapy for patients with fibroproliferative disorders.
57 E prostanoid (EP) receptors in mediating the fibroproliferative effects of IL-1beta in ALI.
58 d serum tryptase were more likely to develop fibroproliferative end organ damage, and 3 of 9 died wit
59 sion subsets described previously, including fibroproliferative, inflammatory, and normal-like groups
60 mprovement were classified as normal-like or fibroproliferative intrinsic subsets.
61 ling that occurs during the development of a fibroproliferative lesion and could facilitate biologica
62 reased levels in cells derived from an early fibroproliferative lesion in a patient with fibrodysplas
63                     Keloid disease (KD) is a fibroproliferative lesion of unknown etiopathogenesis th
64 a knocked out (TNF-alphaRKO) fail to develop fibroproliferative lesions after asbestos exposure.
65                                        These fibroproliferative lesions lead to neointimal thickening
66 ed at 8 to 12 weeks and demonstrated intimal fibroproliferative lesions with a mild parenchymal monon
67 signaling protected the mice from developing fibroproliferative lesions.
68 is associated with accumulation of fibrin in fibroproliferative lesions.
69 s in fibrin gels, an in vitro model of early fibroproliferative lesions.
70 kines are produced during the development of fibroproliferative lung disease.
71 ) is a prevalent, progressive, and incurable fibroproliferative lung disease.
72                    Despite the importance of fibroproliferative lung disorders, no safe and effective
73 re upregulated prior to the development of a fibroproliferative lung lesion, and thus may play a cent
74 s sarcoma-associated herpesvirus (KSHV) in a fibroproliferative malignancy of macaques that has simil
75 roperitoneal fibromatosis (RF) is a vascular fibroproliferative neoplasm which has many morphological
76 insic gene expression subsets (inflammatory, fibroproliferative, normal-like, and limited) are observ
77  In addition, it markedly decreased the late fibroproliferative obstruction in allografts (48%).
78 ration, cartilage erosion, bone erosion, and fibroproliferative pannus) or frozen, cryosectioned, and
79                                          The fibroproliferative phase of acute respiratory distress s
80 CXC chemokines have an important role in the fibroproliferative phase of ARDS via the regulation of a
81 int to a newly described role for HGF in the fibroproliferative phase of RA-associated synovitis.
82 nitis stage and progression into the chronic fibroproliferative phase, leading to pulmonary fibrosis.
83 eases PPM1A expression with acquisition of a fibroproliferative phenotype in each case.
84  suppresses TGF-beta1-induced myofibroblast (fibroproliferative) phenotypic genes, for example, alpha
85  they are not necessary for the formation of fibroproliferative plaques.
86 chiolitis obliterans syndrome is caused by a fibroproliferative process in lung allografts resulting
87 echanistic research has focused on the local fibroproliferative process in the lung.
88 (IH) formation that induces inflammatory and fibroproliferative processes and ultimately restenosis.
89           EGFR activation is associated with fibroproliferative processes in human lung disease and a
90 rombin may be important for inflammatory and fibroproliferative processes in wound healing.
91 ute radiation toxicity and in sustaining the fibroproliferative processes that lead to chronic radiat
92 Angiogenesis and vascular remodeling support fibroproliferative processes; however, no study has addr
93   Concordantly, abrogation of QKI attenuated fibroproliferative properties of VSMCs, while potently i
94 pathic pulmonary fibrosis (IPF) is a chronic fibroproliferative pulmonary disorder for which there ar
95                                          The fibroproliferative reaction to acute lung injury may lim
96                                              Fibroproliferative remodeling in smooth muscle-rich holl
97 mation results from chronic inflammation and fibroproliferative remodeling in the vascular wall.
98 g by ameliorating cell death and stimulating fibroproliferative repair.
99                    One of these involves the fibroproliferative response after acute lung injury, whi
100    Mice deficient in PTEN showed a prolonged fibroproliferative response after tissue injury, and imm
101 U/kg), Stat1-/- mice exhibited a more severe fibroproliferative response and significantly elevated t
102 antial single-cell WNT activity to provoke a fibroproliferative response in adjacent fibroblasts, dri
103 TGF-alpha is associated with a marker of the fibroproliferative response in sustained ARDS.
104                                The excessive fibroproliferative response leading to luminal narrowing
105 atent TGF-beta1, resulting in promotion of a fibroproliferative response over an inflammatory respons
106 tion and that they likely play a role in the fibroproliferative response seen in human acute lung inj
107 ress syndrome (ARDS) frequently results in a fibroproliferative response that precludes effective alv
108                                          The fibroproliferative response to acute lung injury (ALI) r
109                Such mechanisms may drive the fibroproliferative response to ALI.
110 ch Hh-responsive cells accumulate during the fibroproliferative response to chronic cholestatic liver
111 RNA and protein expression and the degree of fibroproliferative response to inhaled asbestos fibers a
112  no soluble TNF-alpha display an accentuated fibroproliferative response to low shear stress (P:<0.05
113                                 Although the fibroproliferative response to lung injury occurs with a
114  and smooth muscle cells, and it reduces the fibroproliferative response to vascular injury.
115 overexpression on liver angiogenesis and the fibroproliferative response using a Tet-inducible bitran
116 cates medial calcification, the inflammatory-fibroproliferative response, and inflammation-mediated e
117                           Matriptase-induced fibroproliferative responses and the receptor involved w
118  that direct TLR9 inhibition mitigates these fibroproliferative responses in our in vivo and ex vivo
119  found that direct TLR9 inhibition mitigates fibroproliferative responses in preclinical models of pu
120  found that direct TLR9 inhibition mitigates fibroproliferative responses in preclinical models of pu
121 was markedly reduced, while inflammation and fibroproliferative responses remained largely intact in
122 e aimed to show that TLR9 activation induces fibroproliferative responses that are abrogated by its a
123 e aimed to show that TLR9 activation induces fibroproliferative responses that are abrogated by its a
124 ies to reduce lung levels of MMP-8 may limit fibroproliferative responses to injury in the human lung
125 n in QKI activity can ameliorate pathogenic, fibroproliferative responses to vascular injury.
126        Thus, we explored the role of CD69 in fibroproliferative responses using a mouse model of peri
127      TLR3-mediated cytokine, type 1 IFN, and fibroproliferative responses were examined in TLR3 wild-
128 ulted in defective cytokine, type I IFN, and fibroproliferative responses.
129                                              Fibroproliferative scars are an important clinical probl
130                     Keloids are pathological fibroproliferative scars resulting from abnormal collage
131  fibrosis are likely to benefit those with a fibroproliferative signature.
132 ve connections between the inflammatory- and fibroproliferative-specific genes.
133 n the inflammatory subset do not move to the fibroproliferative subset, and vice versa.
134 bset and were distinct from the those of SSc fibroproliferative subset.
135          Frozen shoulder is characterized by fibroproliferative tissue fibrosis, whereby fibroblasts,
136 uced heterotopic ossification to examine the fibroproliferative tissue preceding heterotopic bone and
137 fective therapeutic agents for SSc and other fibroproliferative vasculopathies in which EndoMT plays
138 EndoMT may play a role in the development of fibroproliferative vasculopathies.
139 olved in the pathogenesis of the progressive fibroproliferative vasculopathy which is a hallmark of s

 
Page Top